Postantibiotic effect of imipenem on gram-positive and gram-negative micro-organisms. 1986

F Baquero, and E Culebras, and C Patrón, and J C Pérez-Díaz, and J C Medrano, and M F Vicente

The bactericidal effect (BE) of an antibiotic reduces the infective population, and its postantibiotic effect (PAE) assures a persistent inhibition of bacterial cells after a short exposure to the antimicrobial agent. Both effects prevent the early regrowth of the infecting organisms when the antibiotic tissue levels decrease to below the MIC value. The BE and the PAE of imipenem, cefotaxime, ceftazidime, piperacillin, gentamicin and ampicillin on Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Pseudomonas aeruginosa, Acinetobacter calcoaceticus, Staphylococcus aureus and Streptococcus faecalis were investigated with viable counts and continuous impedance monitoring of broth cultures. Imipenem and gentamicin gave similar high BE and PAE values at low concentrations and with short drug exposures in most strains tested. PAE is low or non-existent for Gram-negative strains with other beta-lactam antibiotics. These results suggest the possibility of future clinical studies with new experimental dosage schedules for imipenem.

UI MeSH Term Description Entries
D004926 Escherichia coli A species of gram-negative, facultatively anaerobic, rod-shaped bacteria (GRAM-NEGATIVE FACULTATIVELY ANAEROBIC RODS) commonly found in the lower part of the intestine of warm-blooded animals. It is usually nonpathogenic, but some strains are known to produce DIARRHEA and pyogenic infections. Pathogenic strains (virotypes) are classified by their specific pathogenic mechanisms such as toxins (ENTEROTOXIGENIC ESCHERICHIA COLI), etc. Alkalescens-Dispar Group,Bacillus coli,Bacterium coli,Bacterium coli commune,Diffusely Adherent Escherichia coli,E coli,EAggEC,Enteroaggregative Escherichia coli,Enterococcus coli,Diffusely Adherent E. coli,Enteroaggregative E. coli,Enteroinvasive E. coli,Enteroinvasive Escherichia coli
D006090 Gram-Negative Bacteria Bacteria which lose crystal violet stain but are stained pink when treated by Gram's method. Gram Negative Bacteria
D006094 Gram-Positive Bacteria Bacteria which retain the crystal violet stain when treated by Gram's method. Gram Positive Bacteria
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D013845 Thienamycins Beta-lactam antibiotics that differ from PENICILLINS in having the thiazolidine sulfur atom replaced by carbon, the sulfur then becoming the first atom in the side chain. They are unstable chemically, but have a very broad antibacterial spectrum. Thienamycin and its more stable derivatives are proposed for use in combinations with enzyme inhibitors. Antibiotics, Thienamycin,Thienamycin Antibiotics
D015378 Imipenem Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor. Imipemide,N-Formimidoylthienamycin,Imipenem Anhydrous,Imipenem, Anhydrous,MK-0787,MK0787,Anhydrous Imipenem,Anhydrous, Imipenem,MK 0787,N Formimidoylthienamycin

Related Publications

F Baquero, and E Culebras, and C Patrón, and J C Pérez-Díaz, and J C Medrano, and M F Vicente
June 1998, Antimicrobial agents and chemotherapy,
F Baquero, and E Culebras, and C Patrón, and J C Pérez-Díaz, and J C Medrano, and M F Vicente
November 1998, Antimicrobial agents and chemotherapy,
F Baquero, and E Culebras, and C Patrón, and J C Pérez-Díaz, and J C Medrano, and M F Vicente
October 1999, Antimicrobial agents and chemotherapy,
F Baquero, and E Culebras, and C Patrón, and J C Pérez-Díaz, and J C Medrano, and M F Vicente
October 2009, Antimicrobial agents and chemotherapy,
F Baquero, and E Culebras, and C Patrón, and J C Pérez-Díaz, and J C Medrano, and M F Vicente
February 2009, Antimicrobial agents and chemotherapy,
F Baquero, and E Culebras, and C Patrón, and J C Pérez-Díaz, and J C Medrano, and M F Vicente
November 2006, Antimicrobial agents and chemotherapy,
F Baquero, and E Culebras, and C Patrón, and J C Pérez-Díaz, and J C Medrano, and M F Vicente
September 2005, Antimicrobial agents and chemotherapy,
F Baquero, and E Culebras, and C Patrón, and J C Pérez-Díaz, and J C Medrano, and M F Vicente
March 2003, Antimicrobial agents and chemotherapy,
F Baquero, and E Culebras, and C Patrón, and J C Pérez-Díaz, and J C Medrano, and M F Vicente
March 2009, Antimicrobial agents and chemotherapy,
F Baquero, and E Culebras, and C Patrón, and J C Pérez-Díaz, and J C Medrano, and M F Vicente
January 1994, Chemotherapy,
Copied contents to your clipboard!